Metabolically healthy obesity - focus on endothelium and inflammation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of the study was to evaluate the relationship of adipokines with markers of subclinical inflammation and endothelial dysfunction in patients with metabolic healthy obesity (MHO). Material and methods: our study included 50 persons aged of 25-50 years with obesity in the absence of metabolic disorders (IDF criteria, 2005, marked as MHO), the control group consisted of 50 healthy respondents without obesity. We investigated clinical and biochemical parameters, HOMA-IR index, levels of leptin, resistin, adiponectin, CRP-hs, TNFα, IL6, VEGF, endothelin-1 (ET-1), von Willebrand factor (VWF) in patients under study. Results: in MHO patients, independently of NOMA-IR index, there was an increase of leptin, resistin, VEGF, and IL6 levels. The concentration of CRP-hs and TNF-α was increased in MHO group with HOMA-IR ≥2.7 was increased. Systolic blood pressure correlated with leptin level (r=0,43, p<0,05), TNF-α (r=0,44; p<0,05) and IL6 (r=0,33; p<0,05); diastolic blood pressure - with leptin level (r=0,35, p<0,05). Links between high density lipoproteins and leptin (r=-0,55 and r=-0,60; p<0,01), resistin (r=0,32; p<0,05 and r=0,60; p<0,01) and VEGF (r=-0,70, p<0,01) were established. The VeGf level correlated with HOMA-IR (г=0,62; p<0,01), leptin (r=0,29; p<0,05), resistin (r=0,70; p<0,01), IL6 (r=0,74, p<0,01) and ET-1 (r=0,29; p<0,05). Conclusion: Obese patients without metabolic disorders, having normotension and normal insulin sensitivity, are less influenced to adverse cardiovascular risks due to less expressed hormonal and inflammatory activation of adipose tissue and, as a result, less pronounced endothelial dysfunction. While insulin resistance develops, cardiovascular risk increases due to activation of subclinical inflammation and angiogenic endothelial dysfunction.

Full Text

Restricted Access

About the authors

Sofia G. Shul'kina

E.A. Vagner Perm State Medical University

Email: shulkina-s@mail.ru
MD, assistant professor of the department of internal medicine and outpatient therapy

Elena N. Smirnova

E.A. Vagner Perm State Medical University

Email: elenasm2001@mail.ru
MD, professor, head of the department of endocrinology and clinical pharmacology

References

  1. Драпкина О.М., Елиашевич С.О., Шепель Р.Н. Ожирение как фактор риска хронических неинфекционных заболеваний. Российский кардиологический журнал 2016;6(134):73-79.
  2. Бояринова М.А., Орлов А.В., Ротарь О.П. и др. Адипокины и метаболически здоровое ожирение у жителей Санкт-Петербурга (в рамках эпидемиологического исследования ЭССЕ-РФ). Кардиология 2016;8:40-45.
  3. Национальные клинические рекомендации. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний. Российский кардиологический журнал. Санкт-Петербург 2017;7:6-8.
  4. Bell J.A., Kivimaki M., Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obesity reviews. 2014;15(6):504-51 5.
  5. Wenqing Ding, Hong Cheng, Fangfang Chen et al. Adipokines are Associated With Hypertension in Metabolically Healthy Obese (MHO) Children and Adolescents: A Prospective Population-Based Cohort Study. J. Epidemiol. 2018;28(1):19-26.
  6. Национальные клинические рекомендации. Алгоритм оказания медицинской помощи больным с сахарным диабетом. Под ред. Дедова И.И., Шестакова М.В., Майорова А.Ю. Сахарный диабет 2017;20(1S):10-14.
  7. Шварц В. Воспаление жировой ткани: враг или друг? Цитокины и воспаление. 2013;1(12):13-21.
  8. Пальцев М.А., Кветной И.М., Ильницкий А.Н. и др. Ожирение: молекулярные механизмы и оптимизация таргетной терапии. Молекулярная медицина. 2013;2:3-12.
  9. Amouzou C., Breuker C., Fabre O. et al. Skeletal muscle insulin resistance and absence of inflammation characterize insulin -resistance grade I. obese women. PLoS One.2016;11(4):e0154119.
  10. Smirnova E., Shulkina S., Loran E., Podtaev S. et al. Relationship between skin blood flow regulation mechanisms and vascular endothelial growth factor in patients with metabolic syndrome. Clinical Hemorheology and Microcirculation. 2017:1-14.
  11. Thanigaimani S., Kichenadasse G., Mangoni A.A. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol. 2011; 9(3):358-80.
  12. Шевченко А.В., Коненков В.И. Функциональный полиморфизм генов семейства VEGF. Цитокины и воспаление. 2012;4(11 ): 14-20.
  13. Kaess B.M., Preis S.R., Beiser A. et al. Circulating vascular endothelial growth factor and the risk of cardiovascular events. Heart. 2016;102(23):1898-1901

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies